No Data
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Multiple bullish factors boost pharmaceutical stocks listed in Hong Kong, institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stock market retreats from its high levels, with the Hang Seng Index and the H-share Index both falling by over 1%; the real estate and brokerage sectors decline, Sunac drops more than 9%, Citic Securities falls by nearly 6%.
Network technology stocks decline, NetEase-S drops by 5.61%, Meituan-W drops by 4.05%; Securities and brokerage stocks weaken, CSC drops by 5.45%, China International Capital Corporation drops by 4.34%; Coal industrial concept stocks weaken, China Coal Energy drops by 4.22%, Kinetic Dev drops by 3.18%.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
Hong Kong stock abnormal movement | innovent bio (01801) rose more than 4% in the afternoon, the company terminated the controversial related party agreement, product sales in the third quarter exceeded expectations.
Innovent Bio (01801) rose more than 4% in the afternoon, as of the time of writing, up 4.01%, at HK$38.95, with a turnover of 0.371 billion Hong Kong dollars.
CICC: Maintains innovent bio's 'outperform industry' rating, target price of 58 Hong Kong dollars.
CICC released a research report stating that it maintains a 'outperform industry' rating on Innovent Bio (01801), considering the company's revenue exceeded expectations, raising the 2024 revenue forecast by 5.4% to 8.34 billion yuan, basically maintaining the 2025 revenue forecast at 10.42 billion yuan. Considering the uncertainty of expenses, the 2024/2025 net income attributable to shareholders forecast of -0.78 billion yuan/0.49 billion yuan is maintained unchanged, with a target price of 58 Hong Kong dollars. Event: On October 30, the company announced that 3Q24 product revenue exceeded 2.3 billion yuan, a year-on-year increase of over 40%, exceeding market expectations in the third quarter, mainly due to higher product shipments.
No Data
No Data